A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors
This study is testing a new drug called JAB-2485 to see if it is safe and effective for treating advanced solid tumors. The drug works by blocking a specific protein that helps cancer cells multiply and grow.
This trial is for adults with advanced solid tumors, including certain types of breast or lung cancer, when standard treatments have not worked or were too difficult to tolerate. You must be active enough to handle daily tasks and have a tumor that can be measured on a scan.
Participants will receive the study drug and be closely monitored by a medical team to track how the body reacts and to see if the tumor responds to the treatment. This helps researchers understand the best dose for patients and identify any potential side effects.
The study is currently recruiting new participants at medical centers in Detroit, Michigan; St. Louis, Missouri; and Dallas, Texas.
- 1The study tests a new approach to stopping cancer cells from dividing.
- 2Participation requires that previous standard treatments were unsuccessful for your condition.
- 3Your health will be monitored closely by experts throughout the trial.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.